RF Investment Partners, a provider of flexible growth capital, announced today its platform investment in Altro and Amici Pharmaceuticals, a complementary pair of founder-owned companies that provide strategic sourcing, market insights, and production of generic pharmaceuticals for the growing companion pet and animal end markets. This strategic investment marks RF’s expansion in the healthcare sector as it enters the veterinary and pet-focused pharmaceutical space.
Based in Long Island, NY, “sister” companies Altro and Amici have operated at the intersection of pharmaceutical products and animal health for over 17 years. Altro is a service provider to both veterinary distributors and human generic pharmaceutical manufacturers, while Amici is a virtual pharmaceutical manufacturer with a portfolio of niche products that have uses in both veterinary and human applications. Combining comprehensive industry knowledge with insight into unmet veterinary demand, the companies deliver safe, effective, and affordable products to the industry through their key distribution partners.
RF is partnering with New York-based Aquimont Capital, a healthcare-focused investment firm, and Dallas-based Miramar Equity Partners to support this investment. Known for its specialization in partnering with niche, family-owned businesses, Aquimont brings valuable expertise, operational know-how, and growth opportunities to healthcare businesses.
“During our thorough search for a partner, we sought a group that understood our vision, aligned with our strategic priorities, and elevated our industry experience,” said Aquimont Co-Founders Aron Berke and Nick Lovejoy. “RF exceeded expectations on all accounts, offering ease of close, flexible capital solutions, and a shared commitment to driving organic growth for Altro and Amici. Together, we are honored to build on the strong reputation Altro and Amici have built of providing exceptional customer service and quality products for the pet and human health communities.”
“The simultaneous uptick in pet ownership and increased spending on pet care, combined with RF’s deep healthcare experience, presents a win-win partnership,” shared RF Managing Director Collin Abert. “Altro and Amici have shown impressive growth and innovation in their fields. We are excited to work alongside Aquimont and Miramar, providing a unique debt and equity solution to take advantage of the growing spend, complexity of sourcing, and new opportunities for medications for pet and other animal end markets.”
This acquisition aligns with RF’s mission to invest in high-potential companies that can benefit from flexible growth capital and strategic guidance. RF is actively seeking partnerships with founder-owned and operated pet pharmaceutical and veterinary market leaders. Business owners interested in learning more may contact Collin Abert at cabert@rf-partners.com.
